IFN-α/β Do Not Raise Bcl-2 Levels in Activated T Cells
| Culture conditions . | . | Percentage of Vβ8+ cells alive . | . | Bcl-2 levels in . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vβ8+ cells with . | . | Vβ6+ cells with . | ||||||||||
| CD4 . | . | CD8 . | CD4 . | . | CD8 . | CD4 . | . | CD8 . | ||||
| No Addition | 33.5 ± 0.4 | 11.9 ± 0.3 | 9.1 ± 2.1 | 8.2 ± 1.2 | 13.0 ± 1.6 | 20.6 ± 2.5 | ||||||
| IFN-α/β | 48.0 ± 2.3 | 48.9 ± 1.0 | 7.1 ± 1.3 | 7.9 ± 1.4 | 13.3 ± 1.6 | 24.7 ± 1.3 | ||||||
| IL-2 | 73.3 ± 4.3 | 73.3 ± 4.2 | 18.1 ± 2.1 | 36.5 ± 1.5 | 15.0 ± 1.5 | 39.0 ± 2.7 | ||||||
| IL-15 | 80.7 ± 2.2 | 63.9 ± 2.7 | 23.8 ± 3.7 | 37.8 ± 3.2 | 18.9 ± 2.8 | 49.9 ± 8.5 | ||||||
| Culture conditions . | . | Percentage of Vβ8+ cells alive . | . | Bcl-2 levels in . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vβ8+ cells with . | . | Vβ6+ cells with . | ||||||||||
| CD4 . | . | CD8 . | CD4 . | . | CD8 . | CD4 . | . | CD8 . | ||||
| No Addition | 33.5 ± 0.4 | 11.9 ± 0.3 | 9.1 ± 2.1 | 8.2 ± 1.2 | 13.0 ± 1.6 | 20.6 ± 2.5 | ||||||
| IFN-α/β | 48.0 ± 2.3 | 48.9 ± 1.0 | 7.1 ± 1.3 | 7.9 ± 1.4 | 13.3 ± 1.6 | 24.7 ± 1.3 | ||||||
| IL-2 | 73.3 ± 4.3 | 73.3 ± 4.2 | 18.1 ± 2.1 | 36.5 ± 1.5 | 15.0 ± 1.5 | 39.0 ± 2.7 | ||||||
| IL-15 | 80.7 ± 2.2 | 63.9 ± 2.7 | 23.8 ± 3.7 | 37.8 ± 3.2 | 18.9 ± 2.8 | 49.9 ± 8.5 | ||||||
Lymph node T cells were purified from C57BL/10 mice given SEB 2 d previously. At that time, levels of Bcl-2 were 17.8 ± 0.6 and 17.6 ± 0.9 in Vβ8 cells bearing CD4 and CD8, respectively, and 28.2 ± 0.9 and 38.7 ± 0.9 in Vβ6 cells bearing CD4 and CD8, respectively. Cells were cultured for 24 h alone or with 3,333 U/ml IFN-α/β or 100 ng/ml IL-2 or 100 ng/ml IL-15 and then assayed for intracellular amounts of Bcl-2 as described in Materials and Methods. Results shown are the mean ± SE of staining with anti–Bcl-2 antibody in arbitrary units based on staining intensities of three identical cultures minus the background without primary antibody.